Abstract
Lung cancer is a complex milieu of genomically altered cancer cells, a diverse collection of differentiated cells and nonneoplastic stroma. Lung cancer organoids is a three-dimensional structure grown from patient cancer tissue that could mimic in vivo complex behavior and cellular architecture of the cancer. Furthermore, the genomic alterations of the primary lung tumor is captured ex vivo. Lung cancer organoids have become an important preclinical model for oncology studies in recent years. It could be used to model the development of lung cancer, investigate the process of tumorigenesis, and also study the signaling pathways. The organoids could also be a platform to perform drug screening and biomarker validation of lung cancer, providing a promising prediction of patient-specific drug response. In this review, we described how lung cancer organoids have opened new avenues for translating basic cancer research into clinical therapy and discussed the latest and future developments in organoid technology, which could be further applied in lung cancer organoids research.
Highlights
Introduction of Organoids Models in LungCancer “Lung cancer organoids” refers to the 3D structures processed from lung tumor tissues, containing multiple cell types and growing in an organized manner [32]
Lung cancer remains the leading cause of malignancy-related mortality world-wide [1], and is one of the most prevalent cancer in the world [2]. It could be histologically divided into three major types: nonsmall cell lung cancer (NSCLC), small cell lung cancer (SCLC), and others
Introduction of Organoids Models in Lung Cancer “Lung cancer organoids” refers to the 3D structures processed from lung tumor tissues, containing multiple cell types and growing in an organized manner [32]
Summary
Introduction of Organoids Models in LungCancer “Lung cancer organoids” refers to the 3D structures processed from lung tumor tissues, containing multiple cell types and growing in an organized manner [32]. This genetic drift is a big limitation for patient-oriented drug screening and clinically relevant explorations via lung cancer cell lines. Large-scale study is more difficult to perform in PDX models when comparing with lung cancer cell lines models.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
